Biophytis Signs Contracts with Local Agents in Asia

Biophytis SA, a clinical-stage biotechnology company, has announced its partnership strategy in Asia. The company signed two contracts with local agents: one covering Japan and South Korea, and another for China and Southeast Asia. These agents will help Biophytis identify partners for its drug candidate BIO101 in these markets.

This move aims to accelerate the deployment of BIO101 in Asia, the world's second-largest pharmaceutical market. Biophytis seeks to establish collaborations to address various age-related diseases. Japan and China, with significant populations affected by sarcopenia and obesity, are critical markets for Biophytis.

Following a recent agreement with Blanver in Brazil, Biophytis aims to sign co-development and commercialization agreements with industrial partners in Asia and North America.